1 Safety was assessed by 3 validated bleeding scales (Global Us
2 Safety was assessed by active and passive collection of local
3 In the same population,
safety was assessed by adverse effect monitoring.
4 Safety was assessed by adverse event reporting.
5 Safety was assessed by adverse events (AEs), laboratory tests
6 Safety was assessed by adverse events and clinical assessment
7 Safety was assessed by adverse events and electrocardiogram e
8 Safety was assessed by adverse events, physical examinations,
9 Safety was assessed by adverse events.
10 Safety was assessed by adverse experiences (AEs) occurring du
11 Safety was assessed by blood biomarkers.
12 Safety was assessed by clinical chemistry, blood count and EC
13 Safety was assessed by comparing a baseline basic metabolic p
14 Safety was assessed by comparing rates of adverse events betw
15 In the pilot study,
safety was assessed by determining interobserver and intraobs
16 Safety was assessed by documenting adverse events (AEs).
17 Safety was assessed by evaluating MR images and biopsy specim
18 Safety was assessed by evaluating the presence of adverse eve
19 Safety was assessed by H-E staining, the amount of albumin re
20 Safety was assessed by means including vital signs, cardiovas
21 Safety was assessed by means of complications encountered, an
22 Safety was assessed by means of serial cardiac and thoracic i
23 Safety was assessed by measurement of pulmonary function.
24 Safety was assessed by measuring rates of adverse events, and
25 Safety was assessed by measuring rates of serious adverse eve
26 Safety was assessed by monitoring adverse events.
27 Safety was assessed by monitoring for adverse pregnancy and b
28 Safety was assessed by monitoring laboratory data, including
29 Safety was assessed by monitoring laboratory parameters and a
30 Safety was assessed by monitoring serious adverse events up t
31 Safety was assessed by number of adverse events and serious a
32 Safety was assessed by observing solicited adverse events for
33 ity was assessed by DNA reduction in vitro, and intraocular
safety was assessed by ophthalmoscopy, electrophysiology, and
34 Safety was assessed by queries about side effects at every st
35 Safety was assessed by recording adverse events and by electr
36 Safety was assessed by recording adverse events and with extr
37 Safety was assessed by recording adverse events.
38 Safety was assessed by reports of adverse events.
39 Safety was assessed by standard clinical and laboratory evalu
40 Safety was assessed by standard measures, including treatment
41 Safety was assessed by the frequency of hypoglycaemic events.
42 The primary endpoint of
safety was assessed by the incidence of adverse events and do
43 Safety was assessed by the number of adverse events and clini
44 Safety was assessed by the occurrence of symptomatic intracer
45 Safety was assessed by the rate of acute kidney injury.
46 ssessed the safety and efficacy between the two groups; the
safety was assessed by the systemic reaction (SR) rate.
47 Safety was assessed by use of ex-vivo growth tests of Plasmod